News

FDA warns AstraZeneca about false or misleading claims for Breztri

The U.S. Food and Drug Administration (FDA) has issued a warning letter to AstraZeneca for making false or misleading claims about Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), its approved inhalation therapy for chronic obstructive pulmonary disease (COPD). According to the FDA, promotional material about Breztri distributed by AstraZeneca includes claims…

1st approved Symbicort generic, Breyna, now available in US

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Marpai, NuvoAir partner to provide virtual COPD care to members

Marpai, an artificial intelligence-powered administrator of employer health plans, is partnering with NuvoAir to provide virtual care for heart and lung conditions such as chronic obstructive pulmonary disease (COPD) to its health plan members and their families. “We are thrilled to offer NuvoAir to address the high-cost…